There is no evidence of setting up companies similar to Advent in other countries. Many here believe Charles River Labs will handle manufacturing in the US. With the recent legislation in Brazil, I believe the government lab would handle manufacturing for Brazil. With Flaskworks, this is conceivable. As you know NWBO is Looking at “Franchise” for manufacturing. The Franchisee does not necessarily need to be a company and when you think about it, with Flaskworks the lab doesn’t need to be that special. I believe Chemotherapy Compounding Lab spaces in a typical hospital are clean enough. All they would need is a lab specialist working with Advent to create a generic layout. Then the hospital (like a major hospital in Brazil) would construct the lab space. Then Advent would train their lab technicians and they could create the vaccine. NWBO will keep track of the usage and getting a fee based on their involvement. We have seen patents from many countries. I see this exploding and I see the potential for other countries taking a totally different approach to manufacturing. BP could be edged out of the market for DCVax-L but obviously not for combination therapy. However, when their patents expire, who knows what will happen. All IMO based on the bread crumbs and evidence before us.
Market Data 
Markets 
AI
